Literature DB >> 22275317

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Irene Litvan1, Jennifer G Goldman, Alexander I Tröster, Ben A Schmand, Daniel Weintraub, Ronald C Petersen, Brit Mollenhauer, Charles H Adler, Karen Marder, Caroline H Williams-Gray, Dag Aarsland, Jaime Kulisevsky, Maria C Rodriguez-Oroz, David J Burn, Roger A Barker, Murat Emre.   

Abstract

Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long-term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22275317      PMCID: PMC3641655          DOI: 10.1002/mds.24893

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  57 in total

1.  Complex activities of daily living vary by mild cognitive impairment subtype.

Authors:  Katherine J Bangen; Amy J Jak; Dawn M Schiehser; Lisa Delano-Wood; Elizabeth Tuminello; S Duke Han; Dean C Delis; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

Review 2.  Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure.

Authors:  Marc R Bothe; Ingo Uttner; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2010-01-30       Impact factor: 3.575

3.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

4.  CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Authors:  Guido Alves; Kolbjørn Brønnick; Dag Aarsland; Kaj Blennow; Henrik Zetterberg; Clive Ballard; Martin Wilhelm Kurz; Ulf Andreasson; Ole-Bjørn Tysnes; Jan Petter Larsen; Ezra Mulugeta
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-14       Impact factor: 10.154

5.  Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Authors:  D Aarsland; K Bronnick; C Williams-Gray; D Weintraub; K Marder; J Kulisevsky; D Burn; P Barone; J Pagonabarraga; L Allcock; G Santangelo; T Foltynie; C Janvin; J P Larsen; R A Barker; M Emre
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

Review 6.  Mild cognitive impairment: ten years later.

Authors:  Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2009-12

7.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

8.  BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease.

Authors:  F R Guerini; E Beghi; G Riboldazzi; R Zangaglia; C Pianezzola; G Bono; C Casali; C Di Lorenzo; C Agliardi; G Nappi; M Clerici; E Martignoni
Journal:  Eur J Neurol       Date:  2009-06-15       Impact factor: 6.089

9.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Authors:  Caroline H Williams-Gray; Jonathan R Evans; An Goris; Thomas Foltynie; Maria Ban; Trevor W Robbins; Carol Brayne; Bhaskar S Kolachana; Daniel R Weinberger; Stephen J Sawcer; Roger A Barker
Journal:  Brain       Date:  2009-10-07       Impact factor: 13.501

Review 10.  Neurochemical biomarkers in the differential diagnosis of movement disorders.

Authors:  Brit Mollenhauer; Claudia Trenkwalder
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

View more
  673 in total

1.  Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.

Authors:  Jennifer G Goldman; Holly Weis; Glenn Stebbins; Bryan Bernard; Christopher G Goetz
Journal:  Mov Disord       Date:  2012-07-06       Impact factor: 10.338

Review 2.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

Review 3.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

Review 4.  Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.

Authors:  Katherine Leaver; Kathleen L Poston
Journal:  Neuropsychol Rev       Date:  2015-12-01       Impact factor: 7.444

Review 5.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease.

Authors:  Kazuya Kawabata; Hirohisa Watanabe; Kazuhiro Hara; Epifanio Bagarinao; Noritaka Yoneyama; Aya Ogura; Kazunori Imai; Michihito Masuda; Takamasa Yokoi; Reiko Ohdake; Yasuhiro Tanaka; Takashi Tsuboi; Tomohiko Nakamura; Masaaki Hirayama; Mizuki Ito; Naoki Atsuta; Satoshi Maesawa; Shinji Naganawa; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

7.  How well do MCI criteria predict progression to severe cognitive impairment and dementia?

Authors:  Mary Ganguli; Ching-Wen Lee; Beth E Snitz; Tiffany F Hughes; Eric M McDade; Chung-Chou H Chang
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Apr-Jun       Impact factor: 2.703

8.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

Review 9.  Initial cognitive changes in Parkinson's disease.

Authors:  Daniel Weintraub; Alexander I Tröster; Connie Marras; Glenn Stebbins
Journal:  Mov Disord       Date:  2018-03-15       Impact factor: 10.338

Review 10.  Parkinsonian syndromes.

Authors:  David R Williams; Irene Litvan
Journal:  Continuum (Minneap Minn)       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.